However, more recent studies reported that PML is overexpressed in ccRCC and belongs to gene signatures that identify high-risk patients and correlate with worse disease outcome (Wu et al, 2023; Luo et al, 2023; Wang et al, 2023; Li et al, 2019), implying oncogenic activities. The gene discussed is PML; the disease is nonpapillary renal cell carcinoma.